Meanwhile, on topic: a lie to be refuted, from the
Post# of 72439
One of the worst bashers claims that IPIX has toxic financing.
This is not true. Mr. Ehrlich has gotten a very decent deal with Aspire, particularly since that deal was entered when IPIX was much, much further aways from clinical trials, and had not had this chain of successes. The stock has had VERY little dilution from the financing, and even if we have to use the whole thing, it still is very reasonable dilution for a small biotech.
As far as the claim that "the shareholders should vote [Mr. Ehrlich] out," that is just laughable -- especially given the fact that he is the biggest shareholder in the company.